Skip to content

Study · Animal study (in vivo) · monkey, mouse and rat · 2010

11 results

Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein.

Glaesner W, Vick AM, Millican R, Ellis B, Tschang SH, Tian Y, Bokvist K, Brenner M, Koester A, Porksen N, Etgen G, Bumol T

Diabetes/metabolism research and reviews1 May 2010Cited by 233 (Europe PMC)

PMID20503261 (opens in a new tab)DOI10.1002/dmrr.1080 (opens in a new tab)PepBankPUB-20503261
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In rats and cynomolgus monkeys, LY2189265 had a half-life of 1.5-2 days.

    In plain wordsIn rats and cynomolgus monkeys, LY2189265 had a half-life of 1.5-2 days.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableHalf-life
    Study

    rats and cynomolgus monkeysn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Half-life
    1.5 to 2 days
    rats and cynomolgus monkeys

    Source sentences

    Summary
    Half-life in rats and cynomolgus monkeys was 1.5-2 days, and serum immunoreactivity representing active compound persisted > 6 days.
    1 context sentence
    Summary · context
    In vitro and in vivo activity of LY2189265 was characterized in rodent and primate cell systems and animal models.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In rats and cynomolgus monkeys, serum immunoreactivity representing active LY2189265 persisted more than 6 days.

    In plain wordsIn rats and cynomolgus monkeys, blood signals representing active LY2189265 persisted more than 6 days.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableActive serum immunoreactivity persistence
    Study

    rats and cynomolgus monkeysn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Active compound persistence
    > 6 days
    serum immunoreactivity

    Source sentences

    Summary
    Half-life in rats and cynomolgus monkeys was 1.5-2 days, and serum immunoreactivity representing active compound persisted > 6 days.
    1 context sentence
    Summary · context
    In vitro and in vivo activity of LY2189265 was characterized in rodent and primate cell systems and animal models.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rats, LY2189265 enhanced insulin responses during graded glucose infusion 24 h after one dose.

    In plain wordsIn rats, LY2189265 increased insulin responses to glucose infusion 24 h after one dose.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseInsulin response during graded glucose infusion
    Study

    ratn: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · one doseAs given in this study (rat).

    Source sentences

    Summary
    In rats, LY2189265 enhanced insulin responses during graded glucose infusion 24 h after one dose.
    1 context sentence
    Summary · context
    In vitro and in vivo activity of LY2189265 was characterized in rodent and primate cell systems and animal models.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, LY2189265 increased glucose tolerance after one dose.

    In plain wordsIn diabetic mice, LY2189265 improved glucose tolerance after one dose.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseGlucose tolerance
    Study

    mousen: not reported in source

    diabetic mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · one doseAs given in this study (mouse).

    Source sentences

    Summary
    LY2189265 increased glucose tolerance in diabetic mice after one dose and lowered weight and delayed hyperglycaemia when administered twice weekly for 4 weeks.
    1 context sentence
    Summary · context
    In vitro and in vivo activity of LY2189265 was characterized in rodent and primate cell systems and animal models.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, LY2189265 lowered weight with twice-weekly treatment for 4 weeks.

    In plain wordsIn diabetic mice, LY2189265 lowered weight with twice-weekly treatment for 4 weeks.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBody weight
    Study

    mousen: not reported in source

    diabetic mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    twice weekly · 4 weeksAs given in this study (mouse).

    Source sentences

    Summary
    LY2189265 increased glucose tolerance in diabetic mice after one dose and lowered weight and delayed hyperglycaemia when administered twice weekly for 4 weeks.
    1 context sentence
    Summary · context
    In vitro and in vivo activity of LY2189265 was characterized in rodent and primate cell systems and animal models.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, LY2189265 delayed hyperglycaemia with twice-weekly treatment for 4 weeks.

    In plain wordsIn diabetic mice, LY2189265 delayed high blood sugar with twice-weekly treatment for 4 weeks.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHyperglycaemia onset
    Study

    mousen: not reported in source

    diabetic mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    twice weekly · 4 weeksAs given in this study (mouse).

    Source sentences

    Summary
    LY2189265 increased glucose tolerance in diabetic mice after one dose and lowered weight and delayed hyperglycaemia when administered twice weekly for 4 weeks.
    1 context sentence
    Summary · context
    In vitro and in vivo activity of LY2189265 was characterized in rodent and primate cell systems and animal models.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In monkeys, LY2189265 significantly increased glucose-dependent insulin secretion for up to a week after one dose.

    In plain wordsIn monkeys, LY2189265 increased glucose-dependent insulin release for up to a week after one dose.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseGlucose-dependent insulin secretion after one dose
    Study

    monkeyn: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · up to a week after one doseAs given in this study (monkey).

    Source sentences

    Summary
    In monkeys, LY2189265 significantly increased glucose-dependent insulin secretion for up to a week after one dose, retained efficacy when administered subchronically (once weekly for 4 weeks) and was well tolerated.
    1 context sentence
    Summary · context
    In vitro and in vivo activity of LY2189265 was characterized in rodent and primate cell systems and animal models.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In monkeys, LY2189265 retained efficacy during once-weekly administration for 4 weeks.

    In plain wordsIn monkeys, LY2189265 retained its effect during once-weekly treatment for 4 weeks.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableRetained subchronic efficacy
    Study

    monkeyn: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    once weekly · 4 weeksAs given in this study (monkey).

    Source sentences

    Summary
    In monkeys, LY2189265 significantly increased glucose-dependent insulin secretion for up to a week after one dose, retained efficacy when administered subchronically (once weekly for 4 weeks) and was well tolerated.
    1 context sentence
    Summary · context
    In vitro and in vivo activity of LY2189265 was characterized in rodent and primate cell systems and animal models.
  9. 09AnimalAnimal study (in vivo)Safety outcome

    In monkeys, LY2189265 was well tolerated.

    In plain wordsIn monkeys, LY2189265 was well tolerated.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableTolerability
    Study

    monkeyn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In monkeys, LY2189265 significantly increased glucose-dependent insulin secretion for up to a week after one dose, retained efficacy when administered subchronically (once weekly for 4 weeks) and was well tolerated.
    1 context sentence
    Summary · context
    In vitro and in vivo activity of LY2189265 was characterized in rodent and primate cell systems and animal models.
  10. 10LabEx vivo tissueActivity measurement

    In islets, LY2189265 elicited insulinotropic activity similar to native peptide.

    In plain wordsIn lab tests, LY2189265 stimulated insulin release in islets similarly to native peptide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedInsulinotropic activity
    Study

    n: not reported in source

    islets
    Comparator
    Native peptide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    LY2189265 retained full receptor activity in vitro and elicited insulinotropic activity in islets similar to native peptide.
    1 context sentence
    Summary · context
    In vitro and in vivo activity of LY2189265 was characterized in rodent and primate cell systems and animal models.
  11. 11LabIn vitro (cells)Activity measurement

    In vitro, LY2189265 retained full receptor activity.

    In plain wordsIn lab tests, LY2189265 retained full receptor activity.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableReceptor activity
    Study

    n: not reported in source

    rodent and primate cell systems
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    LY2189265 retained full receptor activity in vitro and elicited insulinotropic activity in islets similar to native peptide.
    1 context sentence
    Summary · context
    In vitro and in vivo activity of LY2189265 was characterized in rodent and primate cell systems and animal models.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.